Associated products


Our Abpromise guarantee covers the use of ab66674 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Form

  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

General Info

  • Alternative names

    • Apo-AI
    • ApoA I
    • ApoA-I
    • APOA1
    • Apolipoprotein A-I(1-242)
    • Apolipoprotein A1
    • Apolipoprotein AI
    • Apolipoprotein of high density lipoprotein
    • ApolipoproteinAI
    • Brp14
    • high density lipoprotein uptake
    • Ltw1
    • Lvtw1
    • MGC117399
    • Sep1
    • Sep2
    see all
  • Function

    Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
  • Tissue specificity

    Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine.
  • Involvement in disease

    Defects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant.
    Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I.
    Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed.
    Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
  • Sequence similarities

    Belongs to the apolipoprotein A1/A4/E family.
  • Post-translational

    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localization

  • Information by UniProt


ab66674 has not yet been referenced specifically in any publications.

Customer reviews and Q&As


Thank you for your inqury.

We have antibodies that are tested and guaranteed for IHC-Fr and ICC which are the main applictaions for indirect immunofluorescence:

ab52945 (or use the following:

ab33470 (or use the following:

ab20918 (or use the following:

ab58924 (or use the following:

ab34788 (or use the following:

Please follow this link if you are interested in purchasing an alternative secondary antibody.

These are the specifications for ab77897, ab80476 and ab77881 for HDL:


HDL2 Subfraction
Not tested for purity
Ultracentrifugation at density 1.063-1.210
100 mM Sodium Chloride, 10 mM Tris, 1 mM EDTA, pH 7.4
1 mM Sodium Azide
Devoid of VLDL, IDL and LDL


Mainly contains apoliprotein AI
purity > 95% by electrophoresis
Sequential flotation ultracentrifugation technique using Potassium Bromide for density adjustments
150 mM Sodium Chloride, 0.01% EDTA, pH 7.4
Essentially free for other plasma lipoproteins


˜equivalent amounts of HDL2 and HDL3
Not tested for purity
Ultracentrifugation at density 1.063-1.210
100 mM Sodium Chloride, 10 mM Tris, 1 mM EDTA, pH 7.4
1 mM Sodium Azide
Devoid of VLDL, IDL and LDL

Difference between ab50239, ab66674 and ab90760 for ApoA-I

ab66674 is only a short pepetide and is only used for blocking purposes and therefore not suitable for your application.

ab50239 and ab90760 are both full length recombinant proteins. Both do not contain preservatives and have a purity > 95%. For ab50239 the endotoxin level has been tested and is less than 0.1 ng per µg (1EU/µg).

I hope this information is helpful and wish you good lucvk with your research.

Read More

For licensing inquiries, please contact

Sign up